Two different tiers of treatment — what that means for you

Comparing ChondroFiller injection with OATS or mosaicplasty can feel like comparing two treatments for the same problem — but they sit in genuinely different tiers of the cartilage-repair pathway, and that distinction shapes everything from the day of treatment to the months that follow.

ChondroFiller injection is an outpatient procedure: ultrasound-guided, no general anaesthetic, completed in under an hour at a clinic. OATS and mosaicplasty are surgical procedures performed in an operating theatre, transferring plugs of the patient's own bone and cartilage into the damaged site. Both aim at the same population — typically active adults under 55 with a focal, full-thickness cartilage defect graded ICRS III or IV in the knee or ankle — but the paths to and from treatment look quite different.

No randomised controlled trial has placed them head to head, so there is no clean hierarchy. The choice turns on specifics: how large the defect is, whether the underlying bone is intact, what recovery the patient can manage, and whether surgery is appropriate or even wanted. Defect size alone — whether it falls below or above roughly 2 cm² — already points strongly in one direction, and subchondral bone involvement can be decisive.

How the ChondroFiller injection works

What gets injected is a liquid — specifically, a clear solution of type I collagen that begins to transform the moment it enters the joint. On contact with the neutral pH environment inside the joint, it self-polymerises within 3–5 minutes into a porous, sponge-like 3D lattice that fills and stabilises the defect from the inside. No heat, no light, and no surgical theatre required: the chemistry is triggered by the body itself.

The scaffold is entirely acellular — no donor cells, no laboratory-grown tissue, no second procedure. It works through matrix-induced chondrogenesis: once the lattice is in place, the patient's own progenitor cells migrate into the porous structure and gradually begin depositing new cartilage matrix. This process unfolds over roughly 6–24 months, and because the collagen scaffold is resorbable, it is progressively replaced as the new tissue matures. Published evidence suggests meaningful symptom relief in 70–85% of treated patients at 3–5 years, though these figures come from observational series rather than large randomised trials.

A clinically important property is its liquid-before-gelling form. Cylindrical grafts used in OATS require a geometrically regular, cored-out recipient site; talar dome lesions, which are often deep, concave, and irregularly shaped, may not accommodate that geometry. Because the ChondroFiller injection arrives as a liquid, it conforms precisely to whatever shape the defect presents — a meaningful advantage for complex ankle lesions that would be technically unsuitable for plug-based surgery.

The procedure takes 30–45 minutes under ultrasound guidance, with no general anaesthetic and no overnight stay. Regarding regulatory status and access, ChondroFiller is a CE-marked Class III medical device with an established period of use in Europe; it lacks FDA approval and is not available in the United States. In the UK it is offered on a self-funded private basis — it is not currently commissioned by the NHS or covered by major private medical insurers.

How OATS and mosaicplasty work

Both OATS and mosaicplasty are built around the same core idea: lift a cylinder of healthy cartilage and bone from a low-load region of the same joint and press it into the damaged site. The transferred material is native hyaline cartilage — structurally denser and more durable under repeated loading than the fibrocartilage scar that microfracture produces. Both procedures are single-stage, meaning harvest and implantation happen in the same operating session with no cell-culture interval.

The distinction between the two techniques is primarily one of defect size. OATS uses a single cylindrical plug — typically 8–10 mm in diameter — suited to defects under approximately 2 cm². Mosaicplasty, introduced in 1992, tiles several smaller plugs side by side in a mosaic arrangement to cover the 2–4 cm² range. Published series have reported good-to-excellent outcomes in around 90% of cases, though a prospective randomised trial subsequently found autologous chondrocyte implantation superior to mosaicplasty for larger or more complex knee defects — a finding that helps define the realistic scope of the mosaic approach rather than undermine its core application.

For ankle OATS specifically, graft is most commonly harvested from the lateral femoral condyle of the ipsilateral knee — a detail many patients encounter only after their pre-operative consultation. Creating a harvest site at a second joint introduces a meaningful risk of donor-site morbidity, including anterior knee pain or stiffness that may persist long-term. Where the talar lesion exceeds approximately 1.5 cm², or where the patient has pre-existing knee concerns, fresh osteochondral allograft (OCA) drawn from donor tissue removes this cross-joint trade-off entirely.

Defect size, location, and subchondral bone — the three selection variables

Three structural features — defect size, defect location, and the state of the bone beneath — do more to clarify the choice between ChondroFiller injection and OATS than any other factor.

Size

Defect size is the single most reliable selection variable. ChondroFiller injection is indicated for focal lesions up to approximately 3 cm², with some published protocols extending this to 6 cm² where the defect geometry allows. OATS covers a broadly overlapping range — roughly 1–4 cm², depending on whether a single plug or mosaicplasty arrangement is used — but it requires a geometrically regular recipient site. Where defects fall into the lower end of this shared range and subchondral bone is intact, both pathways are technically feasible; the remaining variables then carry the decision.

Location and geometry

For ankle osteochondral lesions (OLTs), a specific size threshold has clear clinical significance: lesions below 15 mm in diameter (roughly 150 mm² on MRI) generally respond well to bone marrow stimulation; those at or above that threshold have shown approximately 3% success with marrow stimulation alone, making structural intervention necessary. Because approximately 83% of talar OLTs arise on the medial dome — a concave, curved surface — the geometry of that site is directly relevant. Placing a cylindrical osteochondral plug into an irregularly shaped recess on the talar dome introduces technical demands that have no equivalent when delivering a liquid scaffold that conforms to the space. For lesions on the talar dome within ChondroFiller injection's size range, this conforming property is a genuine clinical advantage, not simply a convenience.

Subchondral bone

When the bone beneath the cartilage is compromised — cystic, collapsed, or structurally thinned — a scaffold that occupies only the cartilage layer cannot address the underlying structural deficit. OATS transfers cartilage and subchondral bone together as a single unit; this is decisive when bone loss is part of the lesion. ChondroFiller injection is indicated where subchondral bone remains intact, and a patient with bone involvement should understand that the injection pathway alone is not designed to replace lost bone.

Patient values as a legitimate clinical variable

For patients who are not surgical candidates — whether due to age, comorbidities, or the absence of a defect large enough to justify theatre — or who place significant weight on avoiding general anaesthesia and a lengthy rehabilitation, the minimally invasive injection pathway is a clinically coherent choice. That said, accepting this route means accepting a thinner long-term evidence base: published ChondroFiller data extends to 3–5 years in observational series; the decades-long follow-up available for OATS does not yet exist for the injection approach.

Recovery timelines and practical trade-offs

Recovery is where the difference between these two pathways becomes most concrete — not in procedure notes, but in the weeks that follow.

ChondroFiller injection is an outpatient appointment: ultrasound-guided, no general anaesthetic, completed in under an hour. The recovery that follows is still a genuine commitment, however: approximately six weeks of protected weight-bearing, meaning reduced walking distances, careful stair use, and no high-impact activity while the scaffold establishes itself inside the defect. Meaningful improvement tends to build gradually, as the collagen matrix matures over six to twenty-four months and the patient's own cells populate it.

Knee OATS or mosaicplasty typically involves crutches for one to two weeks and a post-operative brace for around two to three weeks. Return to high-demand sport generally takes three to six months, depending on defect location and the load pattern of the sport.

Ankle OATS carries a heavier early burden. Strict non-weight-bearing — no load through the foot whatsoever — is maintained for three to six weeks post-surgery. Full weight-bearing typically returns by eight to ten weeks, with high-impact sport at three to six months. On top of this, the knee harvest site has its own recovery arc: anterior knee soreness or stiffness at the collection point — donor-site morbidity, in clinical terms — can persist well beyond the ankle's own rehabilitation window. This cross-joint demand is worth raising explicitly with a surgeon before consenting to the procedure.

One concern patients often raise in consultations is whether choosing the injection pathway now forecloses the surgical option later. It does not. If the defect progresses, fails to respond adequately, or the clinical picture changes, OATS and other structural procedures remain available. The ChondroFiller injection sits at an earlier tier on the treatment pathway — not as a permanent substitute for surgery, but as an option that can be taken first without burning any bridges.

What the evidence shows — and where the gaps are

Neither evidence base is complete — and that is the honest state of the field, not a caveat specific to either procedure.

ChondroFiller injection data derive from observational series and small clinical cohorts rather than large randomised controlled trials. Across published reports, 70–85% of patients achieve meaningful symptom relief at three to five years — a consistent directional signal across multiple joint sites, but one without follow-up data beyond that window. Observational evidence at this scale typically precedes large RCTs by a decade or more; it provides genuine signal, not phase III certainty. ChondroFiller also remains Europe-only: CE-marked and available through specialist centres, but without FDA approval and therefore inaccessible to patients in the United States.

OATS and mosaicplasty carry a longer evidence history. László Hangody's landmark series reported approximately 90% good-to-excellent outcomes, and ten-year comparative data support durable advantage over microfracture in athletes with focal knee defects. A meaningful counter-weight exists, however: a prospective randomised controlled trial found autologous chondrocyte implantation significantly superior to mosaicplasty for larger knee defects, with investigators concluding that the mosaicplasty results 'suggest its continued use is of dubious value' in that setting. The strongest evidence for OATS sits firmly in the 1–2 cm² range; the case weakens as defect size increases beyond it.

No randomised trial directly compares ChondroFiller injection with OATS. Clinicians and patients are navigating that gap using defect characteristics, indirect evidence, and individual risk tolerance — not head-to-head trial data.

The questions worth pressing in any specialist consultation are concrete ones: What does MRI confirm about defect depth and subchondral status? What is the measured defect size on imaging? Those findings do most of the narrowing before any treatment discussion begins. If you would like a clinical view of whether your defect is suitable for the injection pathway, the London Cartilage Clinic on Harley Street offers specialist assessments; further information is at londoncartilage.com.

Ultimately, the decisive variable is not which technique has the longer track record in aggregate — it is whether your specific lesion fits the profile in which either approach has its clearest evidence. That requires imaging, not a comparison article.